The principles of Boron Neutron Capture Therapy
BNCT is a two-step targeted chemo-radiotherapeutic technique that involves the selective delivery of 10 B-rich agents to cancer cells for the purpose of their selective destruction through subsequent irradiation with lowenergy neutrons, which initiate highly localised nuclear fission reactions that do not damage surrounding tissue (Figure 1 ). B per cell) [1] . In order to minimise damage to the vascular endothelial cells and to white matter, the ratios of tumour/blood and tumour/surrounding tissue concentrations must both be higher than 3:1 [2] . Monte Carlo simulations have shown that boron accumulated within the cell nucleus has little effect on neighbouring cells and it is more effective in inducing cell death (ca. 2.5×) than the same amount of boron distributed uniformly within the entire cell [3] .
This suggests that the mechanism of neutron bombardment-initiated damage is determined by the intracellular location occupied by the boronated agent.
Similarly, calculations have shown that boron localised at the cell surface has a ca. 10% lower killing effect than an equimolar quantity of boron that is uniformly distributed within the entire cell [3] . Irradiation of the localised boronated agent with a beam of thermal neutrons leads to each 10 B atom capturing a neutron to form 11 B*, which in turn undergoes nuclear fission to release the energy that induces localised tumour cell necrosis. Consequently, the nuclear reaction of 10 B can effect the selective destruction of malignant tumour cells without compromising the surrounding healthy tissue. The probability of a nuclide capturing a neutron is enumerated by the "neutroncapture cross section" (σ th , measured in barns; 1b = 10 -24 cm 2 ). Offering a good compromise between toxicity and stability, 10 B is characterised by σ th = 3838 b [4] . As compared with X-ray methods, the use of neutron beams is preferred for treatments involving hypoxic cells [5] since the oxygen enhancement ratio (the ratio of radiation doses required to effect the same rate of cell death under oxic as under hypoxic conditions) of neutrons is 1.6 which is lower than that of X-rays (2.5 to 3.0).
The interaction between neutrons and 10 B nuclei generates recoiling 7 Li nuclei and α-particles (also termed Linear Energy Transfer (LET) radiation), which are highly efficient in effecting cell death [6] . Since α-particles are equally lethal to hypoxic or oxygenated malignant cells as they are to surrounding tissue, in order to maximise the relative biological effectiveness the cytocidal effects of the BNCT capture reaction must occur primarily in malignant cells that have preferentially accumulated therapeutically useful amounts of 10 B. Consequent to the short path lengths (4.5 to 10 m) of LET, the lethal effect is confined to the host cell [7] . Inevitable proton capture reactions that involve 1 H and 14 N atoms produce γ-rays and protons, respectively, but the σ th values of these nuclei are too small to be of significance in the therapy of cancer [8] . Because of their greater capability to penetrate tissue, epithermal neutrons have been replacing thermal neutronsthermal neutrons are unable to act on tumours located below the tissue surface because of scattering effects. Epithermal neutrons, which are more energetic (0.5 eV-1.0 keV range) than thermal neutrons, do not suffer from the disadvantages of H-recoil processes and consequently allow capture reactions to occur at some distance within the tissue: epithermal neutrons are progressively slowed into thermal neutrons through heat-releasing interactions with the hydrogen atom constituents of biological tissue that do not caused damage to biological tissue [9] Applications and limitations of BNCT Although there has been interest in the application of BNCT for the treatment of skin [10] and liver [11] tumours, most studies to date have been focused on the treatment of brain tumours, especially glioblastoma multiforme (GBM) [12] ; characterised by rapid regeneration of tumour cells and highly efficient DNA repair mechanisms, the condition is intrinsically resistant to treatment [13, 14] . Since BNCT is associated with the induction of sublethal damage and potentially lethal damage to a non-repairable extent, it has been argued that the technique may act in synergy with surgery [15] .
The multitude of performance requirements that 10 B-containing agents need to satisfy is reflected in the very small number of compounds that have been tested in the clinic. The limited clinical success of BNCT has been attributed to the: absence of sound procedures for the prediction and estimation of radiobiological effectiveness; inefficient methods for the optimization of drug delivery [16] and dosimetry [17] ; random distribution and subcellular localisation of the 10 B-containing agents; and, limited availability of suitable neutron sources [18, 19] . Key examples of clinical trials for the treatment of GBM by BNCT have been presented by Hosmane et al. [19] 
BNCT agents
It has been argued [2] that an ideal BNCT agent should: be systemically non-toxic; be selective in targeting tumour cells (ideally accumulating within specified subcellular structures); persist intracellularly for a period of time that is consistent with the practicalities of the irradiation protocol; deliver the therapeutically optimal amount of ~10 9 10 B atoms/cell; persist at tumour/normal tissues and tumour/blood ratios that are higher than 3:1 and 5:1, respectively; and, be capable of crossing biological membranes (most importantly, the blood brain barrier). To this end, polyhedral boranes have received considerable attention as the molecular moieties of choice for the development of therapeutic agents [20] . Among these, carboranes [21] (icosahedral dicarba-closo-dodecaboranes, C 2 B 10 H 12 ; the focus of this review) are of particular interest since their high 10 B content is combined with good catabolic stability and low toxicity. Also, these materials are amenable to fine tuning through chemical functionalization at each vertex by means of well established chemical methodologies, which have been reviewed elsewhere [22, 23] .
Historical perspective: a promising start
Attempts have been made to classify boronated agents according to key biological properties [24] but the most widely used system for their classification is chronological. Boron compounds are grouped into three generations: the first generation includes water-soluble salts of inorganic borates; the second generation reflects the introduction of polyhedral boranes;
and the third generation encompasses agents that exploit the biochemical pathways through which boronated biomolecular analogues may be accumulated in subcellular structures.
The first generation of BNCT agents included sodium borates [25] , such as borax and pentaborate, and boric acid. These agents presented a lack of selectivity, little persistence in tumour cells and low boron to tumour concentration ratio, which led to their failure, in the 1950s, to progress through clinical trials [24] . Consequent to the observation that paracarboxyphenylboronic acid (PCPB) [26] is not metabolized by the body, and is excreted unchanged through urine, this material was proposed as a candidate agent for BNCT. In a parallel development, para-borophenylalanine (BPA; compound 1, Figure 2 ), a material synthesised by Snyder et al. [27] presented another BNCT candidate material due to its structural similarity to phenylalanine (compound 2, Figure 2 ). ).
Consequent to their aromatic-like nature, these non-planar compounds display remarkable chemical stability. Sodium decahydrodecaborate (Na 2 B 10 H 10 ; GB-10) was recognised immediately as a potential clinical agent for BNCT, since it is less toxic than boric acid (respectively, for GB-10 and boric acid, LD 50 = 1.04 and 2.11 g/kg of body weight) and it presents more favourable tumour/normal cells concentration ratios [31] . This molecule, however, did not meet its promise in clinical tests involving humans, which in turn had significant implications for the direction of BNCT research. The negative results from these trials revealed the sensitivity of the vascular endothelium to LET particles and highlighted the significance of boron concentration in blood during irradiation [32] .
Screening experiments [33] designed to select drugs that give favourable tumour/blood concentration ratios identified the selective tumourcell uptake of sodium dimercaptooctachlorodecaborate (1,10-Na 2 B 10 Cl 8 (SH) 2 ; compound 3, Figure 2 ) and sodium mercaptoundecahydrododecaborate (BSH; compound 4, Figure 2 ). The impetus for further studies was provided by speculation, at the time, that the capability to recognize tumour cells and to promote accumulation may be inherent to the boron cluster structure, or may be linked to ionic charge, or to a specific interaction with certain proteins. The associated research efforts resulted in a third generation of boron compounds, which have been the primary focus of research over the last two decades.
Boron compounds of this generation are designed such that they are rendered capable of reaching and binding to tumour cell receptors efficiently and selectively. Molecular design strategies have evolved to include the selective targeting of epidermal growth factor receptor, mitochondria, lysosomes, and tumour cell nuclei [34, 35] . Integral to molecular design considerations has been the effect of the BBB on the transport of the active ingredient to the brain. The assumption that the BBB becomes permeable to therapeutic agents due to the leaky vasculature of brain tumours was quashed by the observation that isolated clusters of tumour cells, protected by the normal BBB, allow tumour reoccurrence [36] .
From this generation of molecules, two have been advanced to the clinical stages of research, namely: BPA and BSH [37] . BPA has been evaluated as an agent for the treatment of melanomas [38] , gliomas, sarcomas [39] , and meningiomas [40] ; most commonly as a complex of fructose (BPA-F). Evidence has been presented that BPA-F is taken up through the metabolic pathways of the tumour, and also that it displays highly selective accumulation in tumours, low toxicity, few side effects, and, most
importantly, that it is capable of crossing the BBB [41] . BPA-F has been shown to achieve tumour/blood and tumour/brain concentrations ratios of ca.
3.5/1 in 9L gliosarcoma (rat model) [42] ; cell ablation has been investigated [43] . Several studies have been carried out on the intracellular distribution of BPA and according to Nguyen et al. [44] BPA accumulates prevalently in the cytosol but also in the nucleus. In an effort to improve the absolute and relative uptakes of boron in gliomas, the effects of dose and infusion time of BPA on the selectivity of delivery have been investigated [45] . The use of BPA allowed researchers to access tumour boron levels of 70 μg 10 B/g of tumour mass; improvement in therapeutic gain were achieved either by increasing the concentration of boron within the tumour or by increasing the tumour/blood concentration ratio [46] . The route and the administered dose are known to influence therapeutic gain [47] , as demonstrated by studies on the pharmacokinetics and pharmacodynamics of BPA [48] . The chemistry of BPA has been reviewed by Sivaev and Bregadze [49] .
BSH is a small hydrophilic anion, which in contrast to BPA, does not cross the BBB [50] . Used in infusion for the treatment of GBM, BSH has been shown to be not toxic and to be taken up by the tumour in reasonable amounts (tumour/brain ratio >3/1; tumour/blood ratio 0.9/1 -2.5/1) [51] . Slow continuous intravenous infusion was identified as a safer and more efficient means of achieving a high concentration of boron. This technique leads to BSH uptake in malignant gliomas that is about three times higher than that in low grade gliomas [51] . The clinical application of BSH is generally associated with Hatanaka [52] and Nakagawa [53] , who concentrated their efforts in the [54] [55] [56] . The work has been extended to a study that involved the co-administration of BSH with BPA [57] . anion and present aromatic behaviour [21, 58] . The neutral lipophilic icosahedral dicarba-closododecarboranes (C 2 B 10 H 12 ), whose first synthesis was reported independently by workers in the USA [59] and in the former USSR [60] , exist in three isomeric forms: ortho (compound 5), meta (compound 6) and para (compound
Carboranes
The carborane structure consists of two carbon and ten boron atoms that are arranged in an icosahedral geometry in which both carbon and boron are hexacoordinate [61] . Owing to its lipophilic nature, the ortho isomer is the regarded as the moiety of choice for the molecular design of structures that may be capable of crossing the BBB [62] . Carboranes are readily amenable to functionalisation. The boron vertexes are able to participate in electrophilic substitution reactions [63, 64] , such as halogenation. Additionally, protons on carbon atoms may be abstracted by a strong base (pK a (ortho) = 23.3, pK a (meta) = 27.9, pK a (para) = 30.0 -Streitwieser's scale) [65] to form carbon nucleophiles that can be utilised to create C-C linkages [66, 67] . Treatment with a strong base allows the ready conversion of any of the isomeric forms of closo-carboranes into the corresponding hydrophilic nido-carboranes 8, 9, and 10 ( Figure 2 ) by means of a deboronation reaction [68] . While the isomerization reaction of carboranes is not reversible, the transformation of nido-carborane to the corresponding closo-carborane is possible via a capping reaction [69] . Closo-carboranes have been investigated widely because of their high boron content and favourable pharmacokinetic properties, which altogether have rendered them promising candidate agents for use in medicinal chemistry.
Carborane chemistry: the search continues
The significant interest in the synthesis of boronated analogues of biomolecules is consequent to the quest for therapeutic compounds with a capability to accumulate in subcellular structures. To this end, efforts towards the design of carboranyl compounds have concentrated on the mimicing of cellular building blocks (amino acids, sugars, etc.), such as to grant to boron access to cells via normal transport pathways as is exemplified by the classes of carboranyl compounds reviewed below.
Amino acids
Boron-containing amino acids have been investigated for their potential as BNCT pharmacophores. The observation by Endou and Kinai [70] that Lamino acid transport to the tumour tissue site is essential for tumour cell growth rationalised the synthesis of boron-containing alpha-amino acids, such as BPA and o-carboranyl-glycine [71] . The range of synthetic congeners has been extended by Brattsev [72] to ortho-carboranylalanine (CBA; compound 11; Figure 3 ). To the same end, Soloway [73] proposed a more convenient route involving the phase-transfer alkylation of commercial N-(diphenylmethylene) aminoacetonitrile with propargyl bromide, followed by the boronation of the resulting product with decacarborane-acenitrile complex and subsequent hydrolysis. The same synthetic route has been employed for the preparation of para-(ortho-carboran-1-yl)-phenylalanine (CBPA; compound Figure   3 ). Encouraging in vitro results prompted the in vivo testing of these molecules, which at respective tumour/blood concentration ratios of ca. 1.0 and 1.4 did not meet the performance requirements for further evaluation [74] .
12) and O-(ortho-carboran-1-ylmethyl)-tyrosine (CBT; compound 13;
As a consequence of the discovery that the L-isomer of BPA accumulates selectively in melanoma cells, enantiomerically pure L-CBA was prepared [75] , but this material has not been assessed in the clinic because the inherent boron tumour/healthy cells concentration ratio is not within the therapeutically useful range. Morris et al. [76] evaluated the effect of L-BPA prescription dose on the central nervous system (CNS) of the rat model and concluded that a dose of 1600 mg L-BPA/kg is required to optimise the healthy tissue to blood ratio of boron concentration [77] . Efforts towards the optimisation of solubility in serum are informed by earlier attempts towards the improvement of the aqueous solubility of carboranyl aminoacids [71, 78] . Since human thymidine kinase 1(hTK1) is expressed in proliferating cells, Hasabelnaby et al. [79] proposed the use of carrier-linked prodrugs of 3-carboranyl thymidine [80] . Another approach towards the incorporation of boron into tumour-seeking molecules has been explored by the ring opening of cyclic oxonium derivatives of boron hydrides by means of the action of a nucleophilic agent [81, 82] .
In common with naturally occurring amino acids, synthetic structures that combine R-amino acids and amino-boronic acids have been suggested as potential building blocks for BNCT [83, 84] , but the therapeutic promise of such compounds is yet to be demonstrated. Although the amount of research effort invested towards the development of new boronated amino acids has slowed considerably over the last decade, the approach remains validated by the promise of transport across biological barriers, such as the BBB, by dedicated carrier-mediated influx.
Amines and amides
The observation that organoboron compounds inhibit the 20S
proteasome [85] , and also some enzymes such as lipases [86] , Since this class of compounds has been studied widely and because glucose uptake and glycolytic metabolism are amplified in most tumors, this class of compounds merits further investigations.
Nucleic bases
The observation that boronated nucleosides are retained in tumour cells due to their amenability to 5'-monophosphorylation by thymidine kinase 1
and deoxycytidine kinase has provided the driving force for the synthesis of boronated nucleic acids for BNCT applications [94, 95] . Lesnikowski et al. [96] have argued that the performance requirements that inform the molecular design of such molecular structures are the high tagging efficiency of 10 B to tumour cells, the improved lipophilicity of the compound as compared with the precursor nucleoside, and the efficacy of intracellular uptake. To this end, the same workers [96] suggested the addition of a linker between the carboranyl moiety and the 5-position of the uracil group and also proposed that nucleotides are used in conjunction with oligomers, as this compilation imparts resistance to enzymatic digestion, increases lipophilicity and promotes the formation of a stable duplex molecule within the oligonucleotide chain [96] .
Since negatively charged cluster have been shown to adversely influence the ability of nucleosides to cross biological barriers, closocarboranes have received more attention than nido-carboranes [97] . Two main approaches have been adopted in molecular design: the first links the carborane to the ribose portion of the nucleoside, and the second attaches it to the base portion. Because of the lack of selective uptake presented by these compounds, and because of the narrow window of substrate modifications that the enzymes involved in DNA synthesis are able to accept, there are only a few examples of nucleosides bearing a carborane at the ribose site. Nucleosides bearing a substituent at the 5-position (e.g. 5-iodo or 5-bromo-2´deoxyuridine) are very good substrates for enzymes involved in DNA synthesis, and are able to replace thymidine during this process [98] .
Schinazi et al. [99] and Yamamoto et al. [100] respectively synthesised compounds 14 and 22 ( Figure 4 ) and evaluated them in vitro and in vivo.
Compounds 22 effected increased survival in mice, while studies involving enzymes suggested that the cellular uptake of 22 may be mediated by a nucleoside base transporter. Towards the improvement of the targeting specificity of boron compounds [101] , the use of boron-rich carboranyl pyrazole-pyrimidines is reported through tests involving human cell lines to afford improved in vitro binding affinity.
Carborane-decorated pyrimidine rings are known to combine high boron content with good hydrolytic stability. In parallel, quinazolines, which may be regarded as hydrophobic analogues of pyrimidines, are known to display high affinity for the nucleic acids present in tumour cells [102] . Zhou et al. [103] have shown that hydrolytic stability is influenced by the number of hydroxyl-boryl groups in the molecular structure and that the biochemical properties of such compounds are highly sensitive to the presence of bulky aromatic groups. On the basis of this work it has been proposed that the carborane cage may be preferentially linked to the quinazoline group via a thioester linker [104] .
The involvement of nucleic bases in cell processes and their associated ease of uptake by means of dedicated transport systems render these materials candidate carriers of boron for BNCT. However, since enzymes involved in the synthesis of DNA operate within the strict confines of substrate recognition, considerable research effort must be directed towards the establishment of the rules of molecular design.
Triazine derivatives
Several studies have utilised the synthetic versatility of the nucleophilic 1,3,5-triazine ring for the preparation of BNCT agents. Ortho-carboranylthiolate- 
Porphyrins and phthalocyanines
Dependent upon molecular structure, porphyrins have been shown to accumulate into the cytoplasm or at subcellular organelles (mitochondria, lysosomes, the Golgi apparatus, the endoplasmic reticulum or, in some cases, the nucleus) [106] . This property, coupled with low dark toxicity and amenability to activation by red light, renders porphyrins useful photosensitizers for applications in photodynamic therapy (PDT): upon exposure to red light they produce singlet oxygen [107] , triggering mechanisms of cell death by necrosis and/or apoptosis [108] . Studies by Dass et al. [109] and also by Keefe et al. [110] have shown that porphyrins are taken up preferentially by tumours where they become accumulated and persist for prolonged periods of time.
The use of porphyrins in BNCT, first proposed by Dougherty [111] , led to investigations of means for the attachment of porphyrins to boron cages such that targeting specificity may be achieved [112] . One such strategy exploits variations in the expression of High-and Low-Density Lipoprotein (respectively, HDL and LDL). To assess in vivo transport, Polo et al. [113] attached hematoporphyrins to both HDL and LDL. Further studies provided evidence for the LDL receptor-mediated uptake of benzoporphyrin derivatives, but also suggested that the associated acetylation of LDL prevents cellular accumulation [114] . Towards the design of a molecular structure that anchors readily to biological substrates and is capable of inducing damage to DNA and RNA, Eason et al. [115] considered the derivatives of an amphiphilic closo- Vicente et al. [123] studied a 36 boron atom water-soluble mesosubstituted porphyrin (H 2 TCP), which at 100 µM showed no significant cytotoxic effect against murine melanotic melanoma cells in the dark but upon irradiation with red light caused cell mortality at the 20 µM level.
Owing to their structural analogy with porphyrins, some phthalocyanines have been investigated as potential boron carriers [124] , as is exemplified by the boronated metal-phthalocyanine 73 prepared by Kahl et al. [125] ( Figure 5 ).
Delocalized lipophilic cations
Several Delocalized Lipophilic Cations (DLC) are known to accumulate selectively in tumour cells [126] . These include the mitochondrial dye axis [132] .
Following in vivo studies that showed quick uptake, high selectivity (ca.
10× higher than the currently used BNCT agents) and significant retention of triphenylmethylphosphonium iodide in canine brain tumor, the group of Rendina [131] developed a series of water-soluble phosphonium salts containing carborane. The poor aqueous solubility of closo-carboranes led the group to investigate the deboronation and rearrangement of a closo-1,12-dicarbadodecaborane to the zwitterionic nido-7,9-dicarbaundecaborane structure [133] . The work built on that of Hawthorne [134] who had demonstrated the improved water solubility of ionic carborane structures through investigations involving alkylphosphonium-closo-carborane salts. The promise of DLCs as an excellent means of imparting selectivity to boronated agents merits futher investigation, such that the relationships between chemical structure and biology activity are understood in sufficient detail to inform the optimisation strategies to molecular design.
Existing drugs
Several CNS depressants -including promazines, hydantoins and barbiturates -have been investigated as possible carriers of boron for BNCT.
The interest in boronated promazines was first prompted by studies on the localization of chlorpromazine (CPZ) in melanoma-bearing rats [135] . This compound exhibited selective accumulation in tumours (100 μg/g of tumour tissue, a tumour/normal tissue ratio >15) and a half-life of 10 days [135] . In the 1970s, Nakagawa et al. [136] prepared a boronated CPZ analogue by attaching a nine boron atom cage to the nitrogen of the aliphatic chain; but probably because this nitrogen atom is involved in the substrate recognition for the compound's intracellular transit, the results obtained were not very promising. Other boronated CPZ derivatives exhibited acceptable levels of toxicity but disappointing in vivo localization, which has been explained in terms of the accumulation of these chemicals into the liver [137] .
Interest in the preparation of boronated barbiturates and hydantoins has been mainly fuelled by the observation that some of these compounds are able to enter the brain rapidly and achieve high tumour/normal brain concentration ratios. The first boronated barbiturates were synthesised in the 1970s, but it was not until 1998 that Wyzlic et al. [138] observed selective accumulation following the preparation of a boronated barbiturate and hydantoin. However, little evidence was provided to indicate that these compounds possess characteristics that are prerequisite to candidate molecules for clinical evaluation.
Organometallics
Following the discovery of the antitumour activity of cisplatin (cis- Tested against human cell lines in vitro, compounds 38, 39 and 40, which had been synthesised by Tiekink and Bregadze [141, 142] , displayed therapeutic activities that were deemed to be at least comparable with those of cisplatin, carboplatin or methotrexate. Notably, the most water-soluble compound of the series, triphenylstannate sodium salt 40, exhibits the highest cytotoxicity.
In general, issues of low aqueous solubility and high cytotoxicity, even in the absence of neutron irradiation, have hindered the application of carborane-functionalized platinum (II) complexes in BNCT [143, 144] .
In an effort to combine the potential advantages of the two main nuclides that are generally regarded as useful for applications in NCT, namely B and Gd, a complex (GdBLDL) which presents an o-carborane cage and an MRI-probe moiety, Gd-DOTA monoamide, has been synthesised [145] , but the therapeutic promise of the material has yet to be evaluated.
Concluding remarks
To fulfil its promise as the treatment of choice for brain cancers, BNCT Oxygen enhancement ratio: the ratio of radiation doses required to effect the same rate of cell death under oxic as under hypoxic conditions. Potentially lethal damage: DNA damage occurring due to irradiation.
Relative biological effectiveness: the ratio of the doses required by two radiations to cause the same level of effect.
Sublethal damage: sublethal damage is not lethal to cells, but can interact with similar damage from further radiation treatment to produce lethal damage.
Thermal neutron: a neutron that is not bound within an atomic nucleus and that possesses an average kinetic energy of 0.025 electronvolts at room temperature. 
